Sangamo Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Sangamo Therapeutics generated cash of -$224,842,000, which is less than the previous year. Cash used in financing activities reached the amount of $14,588,000 last year. Net change in cash is therefore -$55,240,000.
Cash Flow
| 2014 | -5.67M | -100.65M | 102.17M |
|---|---|---|---|
| 2015 | -33.72M | 77.46M | 19.71M |
| 2016 | -65.88M | 18.12M | 337K |
| 2017 | 11.17M | -80.90M | 97.49M |
| 2018 | 37.15M | -178.10M | 231.70M |
| 2019 | -144.40M | -59.80M | 142.02M |
| 2020 | 169.87M | -271.62M | 153.1M |
| 2021 | -233.25M | 248.19M | 32.85M |
| 2022 | -223.62M | 59.28M | 84.66M |
| 2023 | -224.84M | 153.53M | 14.58M |
SGMO Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 101.94M | 180.37M | 132.82M | 81.92M | 143.91M | 53.32M | 22.06M | 69.48M | 6.03M | 10.18M |
Operating activities | ||||||||||
Net income | -257.83M | -192.27M | -178.29M | -121.12M | -95.41M | -68.88M | -54.56M | -71.65M | -40.70M | -26.41M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 22.19M | 20.56M | 17.63M | 13.36M | 9.60M | 2.35M | 1.49M | 997K | 988K | 549K |
Stock-based compensation expense | 27.36M | 31.65M | 32.95M | 25.70M | 19.33M | 14.67M | 9.08M | 15.05M | 11.73M | 9.2M |
| Deferred income tax benefit | 27.36M | 31.65M | 32.95M | 25.70M | 19.33M | 14.67M | 9.08M | 15.05M | 11.73M | 9.2M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 3.14M | 2.33M | -789K | 31.68M | -32.23M | -1.33M | 1.62M | -2.14M | 7.84M | -7.21M |
Inventories | 0 | 0 | 7.66M | -10.70M | 4.19M | -1M | -685K | -1.02M | 492K | -343K |
Accounts payable | 5.58M | 13.34M | -7.66M | 10.70M | -4.19M | -6.37M | 3.21M | -2.33M | -764K | 4.32M |
Cash generated by operating activities | -224.84M | -223.62M | -233.25M | 169.87M | -144.40M | 37.15M | 11.17M | -65.88M | -33.72M | -5.67M |
Investing activities | ||||||||||
Purchases Of Investments | -59.55M | -277.39M | -338.15M | -570.77M | -443.71M | -451.23M | -252.32M | -218.64M | -257.98M | -227.80M |
Investments In Property Plant And Equipment | -21.15M | -20.17M | -23.27M | -14.71M | -20.67M | -43.06M | -3.75M | -732K | -2.41M | -621K |
Acquisitions Net | 0 | -79.45M | -119K | -704K | -262K | -75.64M | 0 | 0 | -2M | -1M |
Cash generated by investing activities | 153.53M | 59.28M | 248.19M | -271.62M | -59.80M | -178.10M | -80.90M | 18.12M | 77.46M | -100.65M |
Financing activities | ||||||||||
Common Stock Issued | 15.10M | 84.86M | 27.09M | 153.86M | 136.30M | 231.96M | 81.57M | 1.11M | 6.80M | 106.73M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 3.36M | -765K | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 14.58M | 84.66M | 32.85M | 153.1M | 142.02M | 231.70M | 97.49M | 337K | 19.71M | 102.17M |
Net Change In Cash | -55.24M | -78.42M | 47.54M | 50.90M | -61.99M | 90.59M | 27.76M | -47.42M | 63.45M | -4.15M |
Cash at end of period | 46.70M | 101.94M | 180.37M | 132.82M | 81.92M | 143.91M | 49.82M | 22.06M | 69.48M | 6.03M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |